KR101678699B1 - 마시텐탄을 포함하는 치료 조성물 - Google Patents

마시텐탄을 포함하는 치료 조성물 Download PDF

Info

Publication number
KR101678699B1
KR101678699B1 KR1020117003547A KR20117003547A KR101678699B1 KR 101678699 B1 KR101678699 B1 KR 101678699B1 KR 1020117003547 A KR1020117003547 A KR 1020117003547A KR 20117003547 A KR20117003547 A KR 20117003547A KR 101678699 B1 KR101678699 B1 KR 101678699B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
butoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117003547A
Other languages
English (en)
Korean (ko)
Other versions
KR20110045006A (ko
Inventor
마틴 클로젤
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101678699(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20110045006A publication Critical patent/KR20110045006A/ko
Application granted granted Critical
Publication of KR101678699B1 publication Critical patent/KR101678699B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020117003547A 2008-08-13 2009-08-12 마시텐탄을 포함하는 치료 조성물 Active KR101678699B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2008/053252 2008-08-13
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (2)

Publication Number Publication Date
KR20110045006A KR20110045006A (ko) 2011-05-03
KR101678699B1 true KR101678699B1 (ko) 2016-11-23

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117003547A Active KR101678699B1 (ko) 2008-08-13 2009-08-12 마시텐탄을 포함하는 치료 조성물

Country Status (30)

Country Link
US (3) US8809334B2 (enExample)
EP (2) EP3300729B1 (enExample)
JP (3) JP5764061B2 (enExample)
KR (1) KR101678699B1 (enExample)
CN (1) CN102099026B (enExample)
AR (1) AR073031A1 (enExample)
AU (1) AU2009280843B2 (enExample)
BR (1) BRPI0917661B8 (enExample)
CA (1) CA2731370C (enExample)
CY (2) CY1119826T1 (enExample)
DK (2) DK3300729T3 (enExample)
ES (2) ES2763176T3 (enExample)
HK (1) HK1253355B (enExample)
HR (2) HRP20171917T1 (enExample)
HU (2) HUE047767T2 (enExample)
IL (1) IL211143A0 (enExample)
LT (2) LT3300729T (enExample)
MA (1) MA32614B1 (enExample)
MX (1) MX350011B (enExample)
MY (1) MY178894A (enExample)
NO (1) NO2315587T3 (enExample)
NZ (1) NZ591601A (enExample)
PL (2) PL3300729T3 (enExample)
PT (2) PT2315587T (enExample)
RU (1) RU2519161C2 (enExample)
SI (2) SI3300729T1 (enExample)
SM (2) SMT201900740T1 (enExample)
TW (1) TWI446911B (enExample)
WO (1) WO2010018549A2 (enExample)
ZA (1) ZA201101900B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006290309B2 (en) 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
JP5522030B2 (ja) 2008-02-28 2014-06-18 日本新薬株式会社 線維化抑制剤
NO2315587T3 (enExample) 2008-08-13 2018-03-24
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
JP2020502121A (ja) 2016-12-14 2020-01-23 レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 肺高血圧症および他の肺障害の処置のための方法および組成物
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
BR112021011999A2 (pt) * 2018-12-21 2021-09-08 Actelion Pharmaceuticals Ltd Composição farmacêutica para o tratamento de hipertensão arterial pulmonar
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US12485119B2 (en) 2019-11-29 2025-12-02 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
CA3240614A1 (en) 2021-12-31 2023-07-06 Stuart Rich Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
WO2005030187A2 (en) 2003-09-24 2005-04-07 Cotherix, Inc. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) * 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
CN1481244A (zh) * 2000-12-19 2004-03-10 Ĭ��ר���ɷ����޹�˾ 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (enExample) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
BR0316724A (pt) * 2002-12-02 2005-10-18 Actelion Pharmaceuticals Ltd Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
AU2006290309B2 (en) * 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8541433B2 (en) * 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
NO2315587T3 (enExample) 2008-08-13 2018-03-24

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053557A1 (en) 2000-12-18 2002-07-11 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
WO2005030187A2 (en) 2003-09-24 2005-04-07 Cotherix, Inc. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Am J Respir Crit Care Med Vol 165. pp 1209-1216, 2002

Also Published As

Publication number Publication date
MY178894A (en) 2020-10-21
SMT201900740T1 (it) 2020-01-14
PL3300729T3 (pl) 2020-04-30
MX350011B (es) 2017-08-22
BRPI0917661A2 (pt) 2015-12-01
JP2015180683A (ja) 2015-10-15
JP2011530581A (ja) 2011-12-22
CN102099026A (zh) 2011-06-15
BRPI0917661B1 (pt) 2019-12-17
EP3300729B1 (en) 2019-10-09
BRPI0917661B8 (pt) 2021-05-25
SI2315587T1 (en) 2018-04-30
US20110136818A1 (en) 2011-06-09
US9173881B2 (en) 2015-11-03
EP3300729A1 (en) 2018-04-04
ES2763176T3 (es) 2020-05-27
US20160022678A1 (en) 2016-01-28
EP2315587B1 (en) 2017-10-25
US20140329824A1 (en) 2014-11-06
PL2315587T3 (pl) 2018-03-30
HRP20192204T1 (hr) 2020-03-06
MA32614B1 (fr) 2011-09-01
HK1253355B (en) 2020-06-19
HUE047767T2 (hu) 2020-05-28
KR20110045006A (ko) 2011-05-03
HRP20171917T1 (hr) 2018-02-09
CY1122641T1 (el) 2021-03-12
JP5956025B2 (ja) 2016-07-20
AU2009280843B2 (en) 2015-03-05
US8809334B2 (en) 2014-08-19
DK2315587T3 (en) 2018-01-02
JP2015187148A (ja) 2015-10-29
WO2010018549A2 (en) 2010-02-18
JP5764061B2 (ja) 2015-08-12
AU2009280843A1 (en) 2010-02-18
AR073031A1 (es) 2010-10-06
NO2315587T3 (enExample) 2018-03-24
HUE036071T2 (hu) 2018-06-28
DK3300729T3 (da) 2020-01-20
ZA201101900B (en) 2012-08-29
CY1119826T1 (el) 2018-06-27
EP2315587A2 (en) 2011-05-04
PT3300729T (pt) 2020-01-20
MX2011001625A (es) 2011-03-29
CA2731370A1 (en) 2010-02-18
HK1253355A1 (en) 2019-06-14
TWI446911B (zh) 2014-08-01
IL211143A0 (en) 2011-04-28
US9597331B2 (en) 2017-03-21
RU2519161C2 (ru) 2014-06-10
CN102099026B (zh) 2012-08-29
CA2731370C (en) 2017-03-14
LT3300729T (lt) 2020-01-10
RU2011109084A (ru) 2012-09-20
LT2315587T (lt) 2018-01-10
JP5956026B2 (ja) 2016-07-20
TW201010985A (en) 2010-03-16
SMT201700592T1 (it) 2018-03-08
PT2315587T (pt) 2018-01-31
SI3300729T1 (sl) 2020-02-28
WO2010018549A3 (en) 2010-07-29
NZ591601A (en) 2012-12-21
ES2652590T3 (es) 2018-02-05

Similar Documents

Publication Publication Date Title
KR101678699B1 (ko) 마시텐탄을 포함하는 치료 조성물
TWI712409B (zh) 具有增進之治療指數的硝醯基予體
ES2425482T3 (es) Antagonista del receptor de angiotensina II para el tratamiento de enfermedades sistémicas en gatos
EP2029124A1 (en) Use of gpcr agonists to delay progression of diabetes
WO2015127558A1 (en) Methods and uses for inducing or facilitating micturition in a patient in need thereof
RU2367442C2 (ru) Способ нормализации мочеиспускания при нарушении функции почек
JP2013035873A (ja) 神経障害の治療における選択的オピエート受容体調節物質の使用
CN114053281B (zh) 治疗慢性肾病的方法和药物组合物
CN101972230A (zh) 吡非尼酮干混悬剂及制备
HK1157221A (en) Therapeutic compositions containing macitentan
RU2704257C2 (ru) Фармацевтическое применение соединения гексагидродибензо[a, g]хинолизина
JPH0426631A (ja) 血管新生抑制剤
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
CN117919236A (zh) Hdac5抑制剂v014-1478在制备治疗纤维化疾病的药物中的用途
US20030130308A1 (en) Drugs for spinal anesthesia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20191016

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10